MedTrace Logo

A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors

NCT07298772 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 198

Last updated 2026-05-01

No results posted yet for this study

Summary

This is an open label, multi-center, Phase Ib/II study to evaluate the safety, tolerability and efficacy of SHR-4375 injection in combination with other antitumor therapies in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

SHR-4375 Injection

SHR-4375 injection in combination with other antitumor therapies.

Sponsors & Collaborators

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-07
Primary Completion
2027-01-31
Completion
2028-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07298772 on ClinicalTrials.gov